Stock SPRY ARS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 02:52:54 2024-05-28 pm EDT 		5-day change 1st Jan Change
8.825 USD -1.73% Intraday chart for ARS Pharmaceuticals, Inc. -0.11% +60.95%
May. 09 ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 30 ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp CI

Business Summary

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Number of employees: 25

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 96,895,256 68,823,531 ( 71.03 %) 0 71.03 %

Shareholders

NameEquities%Valuation
Deerfield Management Co. LP (Private Equity)
11.48 %
11,077,927 11.48 % 90 M $
RA Capital Management LP
11.25 %
10,860,977 11.25 % 88 M $
Pratik Shah
10.52 %
10,156,204 10.52 % 82 M $
OrbiMed Advisors Private Equity
9.576 %
9,240,887 9.576 % 75 M $
Richard Lowenthal
7.938 %
7,660,306 7.938 % 62 M $
Sarina Tanimoto
5.187 %
5,005,294 5.187 % 40 M $
Robert Bell
4.366 %
4,213,504 4.366 % 34 M $
SR One Capital Management LP
4.158 %
4,012,903 4.158 % 32 M $
Fiduciary Trust International LLC
3.058 %
2,950,963 3.058 % 24 M $
Vanguard Fiduciary Trust Co.
2.991 %
2,886,455 2.991 % 23 M $

Company contact information

ARS Pharmaceuticals, Inc.

11682 El Camino Real Suite 120

92130, San Diego

+

http://www.ars-pharma.com
address ARS Pharmaceuticals, Inc.(SPRY)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for ARS Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.98 USD
Average target price
19 USD
Spread / Average Target
+111.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARS PHARMACEUTICALS, INC. Stock ARS Pharmaceuticals, Inc.
+60.95% 870M
MODERNA, INC. Stock Moderna, Inc.
+52.53% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.41% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+40.01% 40.47B
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 27.17B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.34% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.55% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.83% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.08% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.67% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SPRY Stock
  4. Company ARS Pharmaceuticals, Inc.